StockNews.AISignal intelligence

Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

Browse signals
INBXBullishResearch Analysisnews
High materiality9/10

Inhibrx Reports Strong Interim Phase 2 Data for INBX-106 Therapy

May 11, 2026, 2:16 PM EDT1 sourcesAI-analyzed
Why it may matterVerify against the original reporting

Positive interim results generally increase investor confidence and can drive stock prices higher, as seen historically with successful clinical trials leading to market rallies.

AI summary

What happened, with direct paths to the underlying reporting

The HexAgon study reported a 44% objective response for INBX-106, significantly better than the control's 21.4%. With a Phase 3 start planned for Q3 2026 and expanded indications, the drug's potential market impact is notable.

  • INBX-106 showed a 44% objective response in the HexAgon study.
  • Combination therapy led to deeper tumor reductions in responding patients.
  • Progression-free survival data is expected in Q4 2026.
  • INH will start Phase 3 of the HexAgon study in Q3 2026.
  • New studies for NSCLC and other combinations are planned.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Related signals

More source-backed signals connected by company or event